Skip to Navigation Skip to Search Skip to Content
Search All Centers

Ask the Expert: What Is the Significance of IGHV Mutation Status?

Read Transcript Download/Print Transcript

Published on December 22, 2016

In this “Ask the Expert” segment, a patient asks,  “What is the significance of the IGHV mutation status?  When should newly diagnosed CLL patients get this test?” CLL expert Dr. Jeff Sharman, Medical Director of Hematology Research at US Oncology Network, discusses IGHV and its role in predicting CLL prognosis and disease progression. 

Sponsored through an educational grant from the Patient Empowerment Network, which received support from AbbVie Inc. and Genentech Inc.

Featuring

Sponsors

Patient Empowerment Network

You might also like

Transcript | Ask the Expert: What Is the Significance of IGHV Mutation Status?

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. 

Tamara Lobban-Jones:

Dr. Sharman, a Patient Power member asks, “What is the significance of IGHV mutation status, and at what point should a newly diagnosed CLL patient be tested?”

Dr. Sharman:

So the IGHV mutation analysis oftentimes helps us segregate between CLL that's more likely to be progressive versus not.  It is a little bit of a forecasting marker looking into the future to see how it's going to behave.  It does not change over the course of a patient's CLL, in contrast to FISH.  FISH is really quite dynamic and should be repeated with each new line of therapy. However, IGHV mutation analysis is stable through the course of somebody's CLL. 

We know from patterns of care data from the CLL connect registry that it's actually only tested in less than 10 percent of patients in the United States.  To me, it's actually a very important marker and one that I think is quite standard amongst academic medical center providers who are familiar with CLL, but I think there is a general lack of awareness and understanding of how to use this marker in general practice.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you. 

You might also like